May 30th is officially marked World MS Day. On this day, individuals and organizations from all over the world unite to raise awareness for multiple sclerosis. By making more people understand what life with MS is like, more people will feel compelled to do something about it. Anicells also wants to help finding a solution for this neurological disease and is therefore proud to be the manufacturing partner in a phase I clinical trial with a tolerance-inducing dendritic cell-based therapy conducted by the University of Antwerp and the Antwerp University Hospital. This trial is being carried out as part of the EU-funded ReSToRe project. Today, the last patient has been recruited and 9 patients have received this innovative treatment in Antwerp. The first results of the phase I clinical trial on safety of this innovative cell-based therapy are expected by the end of the year. Anicells looks forward to the results! You too? Then visit the ReSToRe website or follow the project on facebook.